Stockscreener 앱 받기
55.08
2.87%
-1.63
전일 마감가:
$56.71
열려 있는:
$56.48
하루 거래량:
1.41M
Relative Volume:
0.61
시가총액:
$5.25B
수익:
$170.10M
순이익/손실:
$-239.59M
주가수익비율:
-19.67
EPS:
-2.8
순현금흐름:
$-191.20M
1주 성능:
-1.40%
1개월 성능:
+3.34%
6개월 성능:
+17.94%
1년 성능:
+34.11%
1일 변동 폭
$53.76
$56.54
1주일 범위
$53.76
$59.18
52주 변동 폭
$30.04
$78.48
크리스퍼 테라퓨틱스 Stock (CRSP) Company Profile
명칭
Crispr Therapeutics Ag
전화
(617) 315-4600
주소
BAARERSTRASSE 14, ZUG
CRSP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRSP
Crispr Therapeutics Ag
|
55.08 | 5.40B | 170.10M | -239.59M | -191.20M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.90 | 117.47B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.97 | 82.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.59 | 52.94B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
844.92 | 52.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.88 | 37.84B | 447.02M | -1.18B | -906.14M | -6.1812 |
크리스퍼 테라퓨틱스 Stock (CRSP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-18 | 개시 | JP Morgan | Overweight |
| 2025-02-14 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2025-02-12 | 업그레이드 | TD Cowen | Sell → Hold |
| 2025-02-03 | 개시 | H.C. Wainwright | Buy |
| 2024-08-06 | 재확인 | Needham | Buy |
| 2024-08-02 | 개시 | Rodman & Renshaw | Buy |
| 2024-06-28 | 재개 | Guggenheim | Neutral |
| 2024-02-15 | 개시 | Wolfe Research | Peer Perform |
| 2023-12-11 | 다운그레이드 | TD Cowen | Market Perform → Underperform |
| 2023-10-17 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-27 | 개시 | Mizuho | Buy |
| 2023-08-17 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-05-30 | 개시 | William Blair | Outperform |
| 2023-04-13 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-03-21 | 개시 | Bernstein | Mkt Perform |
| 2023-03-17 | 개시 | Bryan Garnier | Buy |
| 2023-03-07 | 개시 | Robert W. Baird | Neutral |
| 2022-10-11 | 개시 | Morgan Stanley | Underweight |
| 2022-08-09 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2022-06-23 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-06-17 | 개시 | BMO Capital Markets | Outperform |
| 2022-04-28 | 개시 | Credit Suisse | Neutral |
| 2021-12-07 | 개시 | Cowen | Market Perform |
| 2021-10-19 | 개시 | SVB Leerink | Outperform |
| 2021-06-14 | 업그레이드 | Citigroup | Sell → Neutral |
| 2021-04-21 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-03-04 | 개시 | JMP Securities | Mkt Outperform |
| 2020-12-10 | 재확인 | Chardan Capital Markets | Buy |
| 2020-12-10 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-12-10 | 재확인 | Needham | Buy |
| 2020-12-07 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-10-23 | 개시 | RBC Capital Mkts | Sector Perform |
| 2020-10-05 | 개시 | BofA Securities | Buy |
| 2020-07-28 | 재확인 | Needham | Buy |
| 2020-07-14 | 개시 | SunTrust | Buy |
| 2020-06-15 | 재확인 | Canaccord Genuity | Buy |
| 2020-03-05 | 개시 | Stifel | Hold |
| 2020-02-03 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-11-19 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2019-11-12 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2019-08-01 | 개시 | Jefferies | Buy |
| 2019-07-26 | 개시 | Canaccord Genuity | Buy |
| 2019-06-10 | 개시 | ROTH Capital | Buy |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-03-14 | 개시 | William Blair | Mkt Perform |
| 2019-01-28 | 다운그레이드 | Goldman | Buy → Neutral |
| 2019-01-22 | 다운그레이드 | Citigroup | Neutral → Sell |
모두보기
크리스퍼 테라퓨틱스 주식(CRSP)의 최신 뉴스
CRISPR Therapeutics Reports Strong 90% Response Rate and Lupus Remission in Landmark Zugo-Cel Update - Finviz
CRISPR Therapeutics AG (CRSP) Stock: ARK Invest Adds Shares as Wall Street Weighs Zugo‑cel Data, Insider Sale, and 2026 Catalysts - ts2.tech
CRISPR Therapeutics Stock (CRSP) in December 2025: Price, Forecast, CASGEVY Growth and Takeover Rumors - ts2.tech
Cathie Wood’s ARK boosts CRISPR stock with significant buy - Investing.com
CRISPR Therapeutics (CRSP) FDA Approvals, PDUFA Dates & Drug Alerts 2025 - MarketBeat
CRISPR Therapeutics (CRSP): Reassessing Valuation After Positive Zugo‑cel Data and New Eli Lilly Collaboration - simplywall.st
CRISPR Therapeutics AG Stock Analysis and ForecastVolume Profile Analysis & Low Entry Investment Portfolio - earlytimes.in
Is CRISPR Therapeutics stock yesterday's news? - MSN
Is CRISPR Therapeutics Stock Yesterday's News? - Finviz
Is CRISPR Therapeutics Stock Yesterday's News? - The Motley Fool
CRISPR Therapeutics AG (CRSP) Stock Falls Amid Market Uptick: What Investors Need to Know - sharewise.com
CRISPR Therapeutics AG (CRSP) stock falls amid market uptick: What investors need to know - MSN
Citizens Reiterates CRISPR Therapeutics (CRSP) Market Outperform Recommendation - Nasdaq
Crispr Therapeutics Insider Sold Shares Worth $559,549, According to a Recent SEC Filing - marketscreener.com
CRISPR Therapeutics (CRSP) CFO reports 10,000-share sale in Form 4 - Stock Titan
3 Brilliant Growth Stocks to Buy Now and Hold for the Long Term - Finviz
CRSP Maintains Market Outperform Rating: Latest Analyst Insights | CRSP Stock News - GuruFocus
CRSP Stock Rises on Encouraging Early Data From Zugo-Cel Studies - Finviz
Early but Compelling CTX112 Data Underpin Buy Rating and $80 Target for CRISPR Therapeutics - TipRanks
Citizens Jmp Reaffirms Market Outperform Rating for CRISPR Therapeutics (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Receives Buy Rating from Needham & Company LLC - MarketBeat
CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112™) in Autoimmune Diseases and Hematologic Malignancies - Sahm
CRISPR Therapeutics CRISPR Therapy Shows 90% Response Rate In Aggressive Blood Cancer - Sahm
CRISPR Therapeutics: Early Autoimmune Promise, Best-in-Class Oncology Data, and Eli Lilly Partnership Support Buy Rating - TipRanks
Crispr Therapeutics provides updates on zugo-cel - TipRanks
CRISPR Says Zugo-cel Well-Tolerated in Phase 1 Autoimmune Rheumatic Diseases Trial - marketscreener.com
CRSP Advances Zugo-cel CAR T Therapy with Promising Clinical Res - GuruFocus
CRISPR Therapeutics Reports Promising Early Results for Zugo-cel in Autoimmune Diseases and Oncology Trials - Quiver Quantitative
CRISPR Therapeutics Provides Broad Update on Zugocaptagene - GlobeNewswire
Entry Recap: Is CRISPR Therapeutics AG stock positioned for long term growth2025 Key Lessons & Real-Time Chart Pattern Alerts - Улправда
How Investors May Respond To CRISPR Therapeutics (CRSP) Earnings Amid Slow Casgevy Uptake Concerns - simplywall.st
What dividend safety rating applies to CRISPR Therapeutics AG (1CG) stockProfit Target & Technical Confirmation Trade Alerts - Улправда
Investor Mood: Is CRISPR Therapeutics AG stock a smart buy before Fed meetingInsider Selling & High Accuracy Investment Signals - Улправда
Trading the Move, Not the Narrative: (CRSP) Edition - news.stocktradersdaily.com
CRISPR Therapeutics AG (CRSP) falls more steeply than broader market: What investors need to know - MSN
Is CRISPR Therapeutics AG stock positioned for long term growthJuly 2025 Reactions & Weekly Watchlist for Hot Stocks - Улправда
Is Trending Stock CRISPR Therapeutics AG (CRSP) a Buy Now? - Yahoo Finance
Is CRISPR Therapeutics a Buy, Sell, or Hold in 2026? - Finviz
CRISPR Therapeutics (CRSP): Reassessing Valuation After a 13% Pullback and Strong Year‑to‑Date Gains - simplywall.st
CRISPR Therapeutics (CRSP): Revisiting Valuation After Recent Share Price Pullback - Yahoo Finance
Is the Market Bullish or Bearish on CRISPR Therapeutics AG? - Benzinga
What analysts say about CRISPR Therapeutics AG stockIndustrial Stocks Review & Minimal Capital Trading Tips - earlytimes.in
Why CRISPR Therapeutics AG (1CG) stock could be next leaderJuly 2025 Spike Watch & Fast Exit and Entry Strategy Plans - Улправда
CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know - sharewise.com
2 Monster Stocks in the Making to Buy and Hold - Finviz
Oppenheimer Reaffirms Outlook on CRISPR Therapeutics (CRSP) After Encouraging Q3 Earnings Performance - MSN
Marex Group plc Invests $948,000 in CRISPR Therapeutics AG $CRSP - MarketBeat
Biomedical Crispr Gene Editing Market Set for Dynamic - openPR.com
Nikko Asset Management Americas Inc. Sells 125,618 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat
Why is CRISPR Therapeutics (CRSP) up 3.3% since last earnings report? - MSN
CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
크리스퍼 테라퓨틱스 (CRSP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.08%
0.21%
자본화:
|
볼륨(24시간):